{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:50:52Z","timestamp":1768546252359,"version":"3.49.0"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T00:00:00Z","timestamp":1463961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Grant Agency of Ministry of Health of Czech Republic","award":["NT1389"],"award-info":[{"award-number":["NT1389"]}]},{"name":"Internal Grant Agency of Medical Faculty University Palacky,Czech Republic","award":["IGA LF_UP_2016_001"],"award-info":[{"award-number":["IGA LF_UP_2016_001"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0155959","type":"journal-article","created":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T18:27:12Z","timestamp":1464028032000},"page":"e0155959","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":22,"title":["Interferon-\u03b1 Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients"],"prefix":"10.1371","volume":"11","author":[{"given":"Vaclava","family":"Polivkova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Rohon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Klamova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Cerna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Divoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Curik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Zach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Novak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iuri","family":"Marinov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Soverini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Faber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Machova Polakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,5,23]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood.V62.3.689.689","article-title":"Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia","volume":"62","author":"M Talpaz","year":"1983","journal-title":"Blood"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/leu.2012.313","article-title":"Re-emergence of interferon-\u03b1 in the treatment of chronic myeloid leukemia","volume":"27","author":"M Talpaz","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"ref3","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-114-7-532","article-title":"Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients","volume":"114","author":"M Talpaz","year":"1991","journal-title":"Ann Intern Med"},{"issue":"8","key":"ref4","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1182\/blood.V79.8.1920.1920","article-title":"Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy","volume":"79","author":"MS Lee","year":"1992","journal-title":"Blood"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","article-title":"Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy","volume":"85","author":"P Rohon","year":"2010","journal-title":"Eur J Haematol"},{"issue":"8","key":"ref6","doi-asserted-by":"crossref","first-page":"e23022","DOI":"10.1371\/journal.pone.0023022","article-title":"Chronic myeloid leukemia patients in prolonged remission following interferon-\u03b1 monotherapy have distinct cytokine and oligoclonal lymphocyte profile","volume":"6","author":"A Kreutzman","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1080\/1042819031000110973","article-title":"Immunological effects of interferon-alpha on chronic myelogenous leukemia","volume":"44","author":"FA de Castro","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"HM Kantarjian","year":"2006","journal-title":"Ann Intern Med"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"A Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer Control"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"A Hochhaus","year":"2002","journal-title":"Leukemia"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"JS Khorashad","year":"2013","journal-title":"Blood"},{"issue":"9","key":"ref12","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","article-title":"Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain","volume":"122","author":"S Soverini","year":"2013","journal-title":"Blood"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"MS Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1073\/pnas.1321173111","article-title":"Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy","volume":"111","author":"DL Gibbons","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7240","key":"ref15","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFNalpha activates dormant haematopoietic stem cells in vivo","volume":"458","author":"MA Essers","year":"2009","journal-title":"Nature"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"e2014006","DOI":"10.4084\/mjhid.2014.006","article-title":"Tyrosine kinase inhibitors and interferon","volume":"6","author":"M Dimou","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia","volume":"38","author":"S Soverini","year":"2014","journal-title":"Leuk Res"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3109\/10428194.2013.812788","article-title":"Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-\u03b1 monotherapy","volume":"55","author":"M Ilander","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00432-014-1845-6","article-title":"Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase","volume":"141","author":"K Machova Polakova","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"M Baccarani","year":"2013","journal-title":"Blood"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"MC M\u00fcller","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"ref22","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.12194","article-title":"Next-generation sequencing\u2014feasibility and practicality in haematology","volume":"160","author":"A Kohlmann","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"NC Cross","year":"2015","journal-title":"Leukemia"},{"issue":"5\u20136","key":"ref24","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cytogfr.2007.06.015","article-title":"The role of interferon-alpha in the treatment of chronic myeloid leukemia","volume":"18","author":"LA Kujawski","year":"2007","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.13151","article-title":"Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia","volume":"94","author":"DH Kim","year":"2009","journal-title":"Haematologica"},{"issue":"8","key":"ref26","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"S Mustjoki","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12185-012-1005-1","article-title":"Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa","volume":"95","author":"H Itonaga","year":"2012","journal-title":"Int J Hematol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0155959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,20]],"date-time":"2020-09-20T22:54:59Z","timestamp":1600642499000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0155959"}},"subtitle":[],"editor":[{"given":"Matthaios","family":"Speletas","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,5,23]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0155959","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,23]]}}}